- Home
- NEXN vs ANAB Comparison
NEXN vs ANAB Comparison
Compare NEXN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXN
- ANAB
- Stock Information
- Founded
- NEXN 2007
- ANAB 2005
- Country
- NEXN Israel
- ANAB United States
- Employees
- NEXN N/A
- ANAB N/A
- Industry
- NEXN Computer Software: Programming Data Processing
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- NEXN Technology
- ANAB Health Care
- Exchange
- NEXN Nasdaq
- ANAB Nasdaq
- Market Cap
- NEXN 636.1M
- ANAB 630.2M
- IPO Year
- NEXN 2021
- ANAB 2017
- Fundamental
- Price
- NEXN $9.65
- ANAB $20.16
- Analyst Decision
- NEXN Strong Buy
- ANAB Buy
- Analyst Count
- NEXN 8
- ANAB 10
- Target Price
- NEXN $14.14
- ANAB $48.00
- AVG Volume (30 Days)
- NEXN 312.4K
- ANAB 427.6K
- Earning Date
- NEXN 11-14-2025
- ANAB 11-04-2025
- Dividend Yield
- NEXN N/A
- ANAB N/A
- EPS Growth
- NEXN N/A
- ANAB N/A
- EPS
- NEXN 0.75
- ANAB N/A
- Revenue
- NEXN $371,746,000.00
- ANAB $123,164,000.00
- Revenue This Year
- NEXN $5.43
- ANAB $11.40
- Revenue Next Year
- NEXN N/A
- ANAB $8.17
- P/E Ratio
- NEXN $13.01
- ANAB N/A
- Revenue Growth
- NEXN 9.65
- ANAB 304.17
- 52 Week Low
- NEXN $6.93
- ANAB $12.21
- 52 Week High
- NEXN $12.60
- ANAB $40.55
- Technical
- Relative Strength Index (RSI)
- NEXN 46.36
- ANAB 41.04
- Support Level
- NEXN $9.48
- ANAB $20.61
- Resistance Level
- NEXN $10.17
- ANAB $23.64
- Average True Range (ATR)
- NEXN 0.31
- ANAB 1.22
- MACD
- NEXN 0.01
- ANAB 0.23
- Stochastic Oscillator
- NEXN 24.64
- ANAB 10.92
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).